{"ticker": {"uuid": "cdb3c370-312c-4b8a-945e-ee6d83327e21", "symbol": "RVMD", "name": "Revolution Medicines Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings Report - Results, Call & Slides", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTFBRRG1qV2VGSWJzeDBHcEpGbjJkRU5rLXAyRmRueDBHS2JVUHJUUXVCRFkxejFWdmZiZ0N6STdLOUluOUp0MWZvcDJhYWp2OXgyN1JPTWZTT1BqRm0xaUVSajhSdzZZeGlDQkJEdA?oc=5", "source_name": "TipRanks", "published_at": "2026-07-22T02:00:49+00:00", "published_display": "22 Jul 2026 02:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines, Inc. (RVMD) Stock Analysis: Why Analysts Are Bullish on This $39.58 Billion Biotech Innovator", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxPeEM0czZYeXNPWGJHOHhjanRYYVhiVGUwcVQ5MlBtRTE1eVIxNEwxY3dRM0pwNXdCYXVnXzBsc2VmLUJFa2lEREs3TTBQcllvVUtXd3owUVc5SHdfdnNCeDJxeFhPTmVMZll5VWpQQTF0VGsxc21WUlI0dXNuSWM3aVY4OVBJSnhtbHlra1I1VEkzZTAxd3BLZDVDb3RxN1JHcU1oMGV1cWdjQklOVG83U1hWV01JOE1wbUFaMVRQRlJ5aG9DVVBUaXRBeWVJblhzT1F4RmJtUlJYYzM2b2tTdHhJd1JyNFNsbWtXQmRQQUJIdw?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-20T09:20:31+00:00", "published_display": "20 Jul 2026 09:20", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Revolution Medicines (RVMD) A Bargain As Daraxonrasib Trial Results Lift Its Outlook?", "summary": "Revolution Medicines (RVMD) is under scrutiny after positive Phase III results for Daraxonrasib and new FDA designations, boosting its stock price significantly. While Simply Wall St's narrative suggests the stock is 39.2% overvalued at $186.16 compared to a fair value of $133.70", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/is-revolution-medicines-rvmd-a-bargain-as-daraxonrasib-trial", "source_name": "Simply Wall Street", "published_at": "2026-07-19T17:10:01", "published_display": "19 Jul 2026 17:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anti-Cancer Upstart\u2019s Stock Surges 125% This Year as Billionaire Druckenmiller Builds Large Position", "summary": "Shares of biotechnology company Revolution Medicines (RVMD) have surged 125% this year, following a significant purchase by billionaire investor Stanley Druckenmiller. The company focuses on developing targeted therapies against previously \"undruggable\" RAS proteins for aggressiv", "url": "https://nai500.com/blog/2026/07/anti-cancer-upstarts-stock-surges-125-this-year-as-billionaire-druckenmiller-builds-large-position/", "source_name": "NAI500", "published_at": "2026-07-18T06:39:54", "published_display": "18 Jul 2026 06:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines Gains as Investors Continue to Digest Clinical and Regulatory Momentum", "summary": "Revolution Medicines (RVMD) saw a 3.1% increase, likely due to continued positive investor sentiment surrounding its pancreatic cancer pipeline. This sentiment follows favorable clinical data updates and a new European regulatory step for daraxonrasib in early July, alongside rai", "url": "https://www.quiverquant.com/news/Revolution+Medicines+Gains+as+Investors+Continue+to+Digest+Clinical+and+Regulatory+Momentum", "source_name": "Quiver Quantitative", "published_at": "2026-07-17T17:35:00", "published_display": "17 Jul 2026 17:35", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "How Investors Are Reacting To Revolution Medicines (RVMD) Pancreatic Cancer Data For RAS G12D Inhibitor", "summary": "Revolution Medicines reported promising Phase 1/2 data for its RAS(ON) G12D inhibitor, zoldonrasib, in metastatic pancreatic cancer, showing high response rates and manageable safety. These early results are crucial as there are no approved targeted therapies for RAS G12D cancers", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/how-investors-are-reacting-to-revolution-medicines-rvmd-panc", "source_name": "Simply Wall Street", "published_at": "2026-07-14T10:40:38", "published_display": "14 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Revolution Medicines Price Target Raised to $235.00/Share From $205.00 by Guggenheim", "summary": "Guggenheim has increased its price target for Revolution Medicines (NASDAQ:RVMD) to $235.00 per share, up from the previous target of $205.00. This revision suggests a strong positive outlook on the company's future performance. Potential investors should consider this updated va", "url": "https://www.moomoo.com/news/post/72723220/revolution-medicines-price-target-raised-to-235-00-share-from", "source_name": "Moomoo", "published_at": "2026-07-09T20:39:41", "published_display": "09 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Better Growth Buy: Axsome vs Revolution Medicines", "summary": "", "url": "https://finance.yahoo.com/m/7d03d2d0-86ef-3916-a00f-62a03fddbe6b/better-growth-buy%3A-axsome-vs.html", "source_name": "Motley Fool", "published_at": "2026-07-09T08:15:00+00:00", "published_display": "09 Jul 2026 08:15", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines (RVMD) Investor Update Summary", "summary": "Revolution Medicines (RVMD) has announced a significant strategic partnership with Royalty Pharma, securing up to $2 billion in funding without equity dilution, which will support independent global development and commercialization of its RAS(ON) inhibitor portfolio. The company", "url": "https://quartr.com/events/revolution-medicines-inc-rvmd-investor-update_oqBrOIQH", "source_name": "Quartr", "published_at": "2026-07-08T21:11:23", "published_display": "08 Jul 2026 21:11", "sentiment": "positive", "sentiment_pct": 76, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines (RVMD) Wins Faster Reviews, Is The Valuation Already Too Rich?", "summary": "Revolution Medicines (RVMD) is under scrutiny after its drug daraxonrasib received accelerated review for pancreatic cancer and partner drug zoldonrasib showed early trial results. Despite a significant recent share price surge, a common valuation narrative suggests RVMD is 42.5%", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/revolution-medicines-rvmd-wins-faster-reviews-is-the-valuati", "source_name": "Simply Wall Street", "published_at": "2026-07-08T20:28:21", "published_display": "08 Jul 2026 20:28", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "European Medicines Agency Expedites Assessment of Revolution Medicines\u2019 Daraxonrasib Under Phased Review Process", "summary": "The European Medicines Agency (EMA) has initiated a phased review of daraxonrasib, Revolution Medicines\u2019 investigational drug for pancreatic cancer, aiming to accelerate its assessment based on promising Phase 3 trial results. Simultaneously, Revolution Medicines is nearing compl", "url": "https://www.globenewswire.com/news-release/2026/07/07/3323317/0/en/european-medicines-agency-expedites-assessment-of-revolution-medicines-daraxonrasib-under-phased-review-process.html", "source_name": "GlobeNewswire", "published_at": "2026-07-07T21:11:23", "published_display": "07 Jul 2026 21:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines Says Pancreatic Cancer Drug Candidate Daraxonrasib Under EMA Phased Review", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/revolution-medicines-says-pancreatic-cancer-135423289.html", "source_name": "MT Newswires", "published_at": "2026-07-07T13:54:23+00:00", "published_display": "07 Jul 2026 13:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines Says EMA Begins Phased Review of Daraxonrasib for Pancreatic Cancer as FDA NDA Submission Nears Completion", "summary": "Revolution Medicines announced the European Medicines Agency (EMA) has initiated a phased review of its investigational drug, daraxonrasib, for pancreatic cancer, following positive Phase 3 trial results. The drug, designated as an orphan medicinal product by the EMA and a priori", "url": "https://www.quiverquant.com/news/Revolution+Medicines+Says+EMA+Begins+Phased+Review+of+Daraxonrasib+for+Pancreatic+Cancer+as+FDA+NDA+Submission+Nears+Completion", "source_name": "Quiver Quantitative", "published_at": "2026-07-07T13:31:00", "published_display": "07 Jul 2026 13:31", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EMA fast-tracks Revolution Medicines' pancreatic cancer drug review", "summary": "The European Medicines Agency (EMA) has initiated a phased review of Revolution Medicines' investigational drug, daraxonrasib, for pancreatic cancer to expedite its assessment before a full marketing authorization application. This decision is based on positive Phase 3 data from ", "url": "https://www.stocktitan.net/news/RVMD/european-medicines-agency-expedites-assessment-of-revolution-e06zedp7v6mt.html", "source_name": "Stock Titan", "published_at": "2026-07-07T13:11:39", "published_display": "07 Jul 2026 13:11", "sentiment": "positive", "sentiment_pct": 81, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "European Medicines Agency Expedites Assessment of", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAJBVV95cUxOSzkzeWx6T01OT0h0dWVGcHZadkRxY043RGhrdEMwWEpSU3RWWHFWeFNyNXdGS3JRcXZIRnVhSlZKWWE4d0dseDFJTWdzOFpBSkpJTG5JUmE3QUtrY21MMUZWeWtXVFBNUG9UY3hIZks2MnNZcmJ0MTBxODh0VmxybXd2aTlrczJDd1V1WXE5MnFLcm81VmlDdlBlc1RIS3hHLTFWZ0hxak1NU2p5bGNYQ1ZZWFoyWnpMUEl5dXZGUEtEclFGZWQyVVFWRTBCUi1XNkJVbFRVay1xanNORmN4c08wMjFZWjhOSWRsM2VNTE12WFRhSmNkTkFvazExQk1PaU9YU0JCQUpHOVJUZEtYVg?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UBS Adjusts Price Target on Revolution Medicines to $220 From $175, Maintains Buy Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ubs-adjusts-price-target-revolution-141129509.html", "source_name": "MT Newswires", "published_at": "2026-07-06T14:11:29+00:00", "published_display": "06 Jul 2026 14:11", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines stock hits all-time high at 193.12 USD By Investing.com", "summary": "Revolution Medicines Inc. stock has reached an all-time high of $193.12, trading just 1% below its 52-week high, marking a significant 424.05% increase over the past year despite being deemed overvalued by InvestingPro. This surge follows positive Phase 1/2 clinical trial results", "url": "https://za.investing.com/news/stock-market-news/revolution-medicines-stock-hits-alltime-high-at-19312-usd-93CH-4356694", "source_name": "Investing.com South Africa", "published_at": "2026-07-06T14:41:44", "published_display": "06 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Raises Price Target on Revolution Medicines to $215 From $185, Keeps Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/mizuho-raises-price-target-revolution-100609977.html", "source_name": "MT Newswires", "published_at": "2026-07-06T10:06:09+00:00", "published_display": "06 Jul 2026 10:06", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Raises Price Target on Revolution Medicines to $181 From $165, Keeps Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wedbush-raises-price-target-revolution-100418728.html", "source_name": "MT Newswires", "published_at": "2026-07-06T10:04:18+00:00", "published_display": "06 Jul 2026 10:04", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?", "summary": "Revolution Medicines (NASDAQ: RVMD) has seen its stock price surge by nearly 140% in 2026 due to promising late-stage clinical trial results for its cancer treatments, which target previously \"undruggable\" RAS proteins. The company's lead candidate, daraxonrasib, has shown signif", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/motley/3134995/revolution-medicines-is-up-nearly-140-in-2026-is-the-hot-biotech-stock-still-a-buy/", "source_name": "The Globe and Mail", "published_at": "2026-07-06T07:41:44", "published_display": "06 Jul 2026 07:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Strong Early Zoldonrasib Pancreatic Data Change Revolution Medicines' (RVMD) RAS-Focused Narrative?", "summary": "Revolution Medicines reported positive Phase 1/2 data for its oral RAS(ON) G12D inhibitor zoldonrasib in pancreatic cancer, showing high response rates and manageable safety in combination with other treatments. These results support ongoing and planned global Phase 3 trials, str", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/will-strong-early-zoldonrasib-pancreatic-data-change-revolut/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-06T06:39:46", "published_display": "06 Jul 2026 06:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines: A $40 Billion Bet on a Cancer Breakthrough, But At What Price?", "summary": "Revolution Medicines (NASDAQ: RVMD) has seen its market capitalization surge to $40.23 billion due to groundbreaking Phase 3 trial results for its lead cancer drug, daraxonrasib, which showed unprecedented efficacy in metastatic pancreatic cancer. Despite having no revenue and co", "url": "https://www.kavout.com/market-lens/revolution-medicines-a-40-billion-bet-on-a-cancer-breakthrough-but-at-what-price", "source_name": "Kavout | AI", "published_at": "2026-07-06T05:41:50", "published_display": "06 Jul 2026 05:41", "sentiment": "positive", "sentiment_pct": 81, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines, Inc. Warrant Financial Disclosures & SEC Filings", "summary": "This page provides access to Revolution Medicines, Inc. (RVMDW) financial disclosures and SEC filings, including Forms 10-K, 10-Q, 8-K, and other key documents. The filings highlight significant company events such as study results for Daraxonrasib, quarterly earnings, and partic", "url": "https://www.tradingview.com/symbols/NASDAQ-RVMDW/documents/", "source_name": "TradingView", "published_at": "2026-07-05T07:10:29", "published_display": "05 Jul 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026", "summary": "Revolution Medicines, Inc. announced promising Phase 1/2 clinical data for zoldonrasib combination regimens in patients with RAS G12D metastatic pancreatic cancer. The results, presented at the ESMO Gastrointestinal Cancers Congress 2026, show compelling efficacy and manageable s", "url": "https://www.globenewswire.com/news-release/2026/07/02/3321282/0/en/Revolution-Medicines-Presents-Phase-1-2-Clinical-Data-for-Zoldonrasib-Combination-Regimens-in-Patients-with-RAS-G12D-Metastatic-Pancreatic-Cancer-at-ESMO-Gastrointestinal-Cancers-C.html", "source_name": "GlobeNewswire", "published_at": "2026-07-03T06:39:49", "published_display": "03 Jul 2026 06:39", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines Reports 82% Response Rate for Zoldonrasib in Metastatic Pancreatic Cancer", "summary": "Revolution Medicines presented promising Phase 1/2 data for zoldonrasib in metastatic pancreatic ductal adenocarcinoma (PDAC), showing an 82% objective response rate with zoldonrasib plus modified FOLFIRINOX in first-line treatment. The company is advancing two simultaneous Phase", "url": "https://www.clinicaltrialvanguard.com/news/revolution-medicines-reports-82-response-rate-for-zoldonrasib-in-metastatic-pancreatic-cancer/", "source_name": "The Clinical Trial Vanguard", "published_at": "2026-07-03T06:39:00", "published_display": "03 Jul 2026 06:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines (RVMD) Reports Phase 1 2 Pancreatic Cancer Data That Sets Up Phase 3", "summary": "Revolution Medicines (RVMD) has reported promising Phase 1/2 trial data for its RAS(ON) inhibitor combinations, zoldonrasib and daraxonrasib, in metastatic pancreatic cancer. The data showed strong antitumor activity and manageable safety, particularly in patients with RAS G12D m", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/revolution-medicines-rvmd-reports-phase-1-2-pancreatic-cance", "source_name": "Simply Wall Street", "published_at": "2026-07-03T03:10:14", "published_display": "03 Jul 2026 03:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines sees large block trade worth $196.7 million", "summary": "Revolution Medicines Inc. experienced a large block trade of 1.06 million shares, representing 0.5% of its float, valued at $196.7 million. The transaction took place at a 1.3% discount from the opening price. Despite a 0.9% decline on the day of the trade, the stock has gained 1", "url": "https://www.investing.com/news/stock-market-news/revolution-medicines-sees-large-block-trade-worth-1967-million-93CH-4773894", "source_name": "Investing.com", "published_at": "2026-07-02T19:10:14", "published_display": "02 Jul 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines reports trial results for pancreatic cancer drug", "summary": "Revolution Medicines Inc. announced positive results from two Phase 1/2 clinical trials for zoldonrasib in combination regimens for RAS G12D metastatic pancreatic ductal adenocarcinoma. The trials showed promising objective response rates and progression-free survival, supporting", "url": "https://www.investing.com/news/company-news/revolution-medicines-reports-trial-results-for-pancreatic-cancer-drug-93CH-4773016", "source_name": "Investing.com", "published_at": "2026-07-02T13:13:19", "published_display": "02 Jul 2026 13:13", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines reports zoldonrasib pancreatic cancer data", "summary": "Revolution Medicines reported a high treatment response rate of up to 82% for its zoldonrasib combinations in patients with RAS G12D metastatic pancreatic cancer, causing company shares to rise. These Phase 1/2 data, presented at the ESMO GI 2026 Congress, support the initiation ", "url": "https://grafa.com/en/news/united-states/evolution-medicines-zoldonrasib-esmo-2026-data", "source_name": "grafa.com", "published_at": "2026-07-02T13:13:19", "published_display": "02 Jul 2026 13:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines shows 82% response in pancreatic cancer combo trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPRnpqQ0R6bmcxOVJlVDhJaFVzZWlZZFRLc1FBUnJUVlB2RFNfWjR4ekl5OUNrSE1sbGdvSGtQNHJwZF8wM2VZQ1JfWk5SdG5wMzYtNERaOVdTdkJ1cm5YTEtkM1FVZzlENTgwZWdsenJ0WHRnaFdnMFRiWERWWWdkLWFuX2NiMDdpbER6LWwyaUlWYURFVTVBSmNkX0NUa1ZpUVVfUDNfNTFkWmZOUFVWR01R?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Revolution Medicines Inc For: 1 July By Investing.com", "summary": "This article announces the filing of Form 4 for Revolution Medicines Inc. on July 1st. It also provides a market overview with current values for various indices, commodities, and bonds, along with trending news and market movers. The primary content focuses on the Form 4 filing ", "url": "https://ca.investing.com/news/stock-market-news/form-4-revolution-medicines-inc-for-1-july-93CH-4717303", "source_name": "Investing.com Canada", "published_at": "2026-07-01T22:40:48", "published_display": "01 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines (NASDAQ: RVMD) director sells 5,580 shares, exercises options", "summary": "Revolution Medicines director Sushil Patel exercised stock options for 2,955 shares and sold 5,580 shares of RVMD common stock on June 29, 2026. The sales were part of a pre-arranged Rule 10b5-1 trading plan and were executed at weighted-average prices ranging from $182.93 to $19", "url": "https://www.stocktitan.net/sec-filings/RVMD/form-4-revolution-medicines-inc-insider-trading-activity-4823e9b9162c.html", "source_name": "Stock Titan", "published_at": "2026-07-01T22:40:48", "published_display": "01 Jul 2026 22:40", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines director Sushil Patel sells $1.05m in stock By Investing.com", "summary": "Revolution Medicines director Sushil Patel sold $1.05 million worth of company stock through a pre-arranged trading plan, following the exercise of stock options. These sales occurred when the stock was trading near its 52-week high, with InvestingPro analysis suggesting the stoc", "url": "https://ca.investing.com/news/stock-market-news/revolution-medicines-director-sushil-patel-sells-105m-in-stock-93CH-4717300", "source_name": "Investing.com Canada", "published_at": "2026-07-01T22:40:48", "published_display": "01 Jul 2026 22:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Revolution Medicines, Inc. \u2013 NASDAQ:RVMD", "summary": "This article provides a brief financial update for Revolution Medicines, Inc. (NASDAQ: RVMD), focusing on its forward price-to-sales ratio. It indicates current trading information and highlights that the market is closed with no recent trades. The content is primarily a data poi", "url": "https://www.tradingview.com/symbols/NASDAQ-RVMD/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T18:13:20", "published_display": "01 Jul 2026 18:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Revolution Medicines, Inc. \u2013 BMV:RVMD", "summary": "This article provides the \"Price to earnings forward\" metric for Revolution Medicines, Inc. (BMV:RVMD). The content appears to be a financial data point from TradingView, indicating that the market for RVMD was closed with no trades recorded at the time of publication. The articl", "url": "https://www.tradingview.com/symbols/BMV-RVMD/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T05:41:01", "published_display": "01 Jul 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines rises as investors focus on fresh pancreatic cancer pipeline updates | RVMD Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQTjJhc1RHdUhtRXl2Vk5vMm5ZUVI3blRNNTZtbWJsSnpEdjJQelAyRWtCOE1zUXBLUHp5enFyT3ZwUlZaM3BFSkIyRkNKWXBZNF9LU183ZmpOR2xwcWRwb1pHdUtMQlVleUNBNG9fSWcxXzdTRjd5WG5xY1h5RndXUkFWUzFYWm85dHdfWVhJX09TMHRNOVJiTjBnZHdvbzVDXzZUMWtVMzVWSGQ5VThWTXdkMVdEeGpVbHhYX3hGVQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines (NASDAQ: RVMD) insider sells 132,871 shares totaling $19.29M", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOeXJOM2Q2RHZ4ZTNRWGVnWVlOOFh5MEY2THRKZ0tKVVJJc0JuX0tSNU9lblNsNVJVeU85VDkzM2gzR21weUEwUllZYmhDTmoxSDBCdWwyUnEzYUJTTGswSEkzb0JfT0JWc3QxUW1CaWlmSV9BbFdMR3hPN0dHenA2dHVGZnQzLTZLdEYtSXg0dnBmUmNrYzhYUnNHck1Mc09lVkRj?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pancreatic Cancer Drug Milestone Affirms Why Revolution Medicines Inc. (RVMD) is a Hot Stock to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOdUk5S3UzVVgzN1dyVmZ6Nk11N2ZJZklSdTRLZDctSnJtWmJPWVJrTVNMUHA2OFlCVTdHeEFBcXhpRk9PbjRKWTRqVVg3NDFvTjBFZGZQV2RLeDl6Qnd2dE9XYjYxQlRjSWNJSmZYUnJlNVFodHFlQ2czNW4tamdGSm42MFpiVmpoNkhGN1BlLVc4WHFlTThabDZNM2FhRkRZVzNWNVR0WXI?oc=5", "source_name": "Market source", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Revolution Medicines (RVMD) The Best Biotech Stock According to Billionaire Stanley Druckenmiller?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPSTEwbTZXc3lzQXVHdko4YlVDeElMY2JxeWF5R1FPdEVYNi1aVTFPY05JejdBdzVtakYxMVRjeHloR0V1T3FSZEVWSmdwVGxvWXhxSTBJUjQ2Q2xINlBIS3NVZjR2VzVpT3dWUmVlY1FxWjA0Zl9oV2NETFpLeExnWXBzRmlod0doSHpjOUZtbXFiQ2ZGckh2UXR2cHNaaTM4aE9mRXNlR3NCLUU?oc=5", "source_name": "Market source", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNSlhiWmpkRnRZdFZnR1lia0lUcHJRUlJXcXNIWlRNcEFNaTQwWUxDSzNhekZoOEFyMHlhQ0ROaVYtQlRDMjlVaTlKNWJaY3NsTXJfbWduU2tsRkowN2g4c2dTRFRqLXJZM0ExUjV1aTE1RGxkd2NITk93MGZHbGkydjQ5aWZud015NlZXa1c4M1RXTC1oV1JSMVYxNUc?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Daraxonrasib\u2019s Phase 3 Pancreatic Cancer Data And EQRx Deal Altering The Investment Case For Revolution Medicines (RVMD)?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQVEc2R3BwX25pQ20weXhtVVMwcVQ2TlRRYWhBZmx4dm9nZlc4UnRBT2RIT0RCRGdaSlBEZTBtdVk0dFVCNmZSYkhfQ19DVF9CYXIzQVdBY25rM0JUbkdBdm5mRmg5RmxGZ1djdGJ2V0pWQ3FwV3hpWTg0bTJPR0hPbXQzTVlLcFE3bkRZRkg0X3I4WTNZdV8yS1hDOTA4VWZUb2N2cVE4UXRSVUU?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janus Henderson Group reports stake in Revolution Medicines (RVMD) \u2014 9.77M shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOZThwN1NMZ0N6R1p1YjNGb0xFcmxHQkNYRlVIMlJ2NEx3VWtCZmRROXQ3MnRZc0plSVdZQ2xuX18ycFp1OFpJUzBLb2VpTEI0NEhYWUNxMktyTXkxNjFiSTZ4YXhnT2hpa1ZseFc1R0ZacTV3TXhsdnpZZjRVNi02aWhwVWdIOXA0T296QTR1ZHcxSW1sYjNBay0xbi15RE91VE9DZEFWOEFobzZINVduNVZldHdfbDcxdkx0emRRYWZWY3c5clM3VE52NA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug By Reuters", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxPY09oc3ZUaGpNckRvaWdkYWRLSnJEa1Q0MTc3OFRTSlh3aHczR1N6Q2l3MktXSGZxN1VRLTRlcGVEZTh1YWcxbVhKdGpYM2NDT1VsTWljaGRmRzNFb3N2OVZJcDBIa0drOVdTUWR4ZjB3bEVfd2lNSnkwcHJmeWJaQWhuRlY4WTZiYmdWeXdoM0VzRVRQT1hhSUJaS2dIOWlBaG5rVGhvYVE2bmM1b3JpdnhYYVdUWEtFcjhXNEhhc09BTDAtTnhMUTR3aFpmVF9EdFRQUTZMZ2twN3lhNFEyLQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is It Too Late To Consider Revolution Medicines (RVMD) After Its Recent Surge In Price?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines (RVMD) Receives FDA\u2019s \u201cSafe to Proceed\u201d Letter for Daraxonrasib", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPM2ZnTzVXbnUzakN2STBHRVVaN0xDdUxmTUtISHVnODhUUklFbnQ2S3NRcjF2YzV5eUphcER0SE4temo0bTVzMFZObHJRaXFTNVItVnVJbzZZcnBWWWFsbXFIUVU5aEpDLXVCRUU0ckFNdFltSlRaaVdYcXpMS0tuNl9UeXg0c0xHOVp3UzlyUlRvNzRUUVgtaVdIblZRem9xQTE1cUdOVVg0WWM?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines, Inc. (RVMD) One of the Best Stocks to Buy in a Rising Market amid $14B Opportunity", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNQl9JUzd3YmpuNFl6clZyRTMwU3MyZmNmeWJOb04za2hyaGp6aWwxZDhCVG1VMXprdkNyUGhMMk9HcS1oazBBbnNVbGZ6NTZ5bEVlNWVseVMwT19SUE5ST2lYZTVKQXdCU3hqTkhQSG44VUpLdlVkZmU2Z0d6QmJfNjBidmNfTzZRWDZySHRPY0prclZWa0dSOHBHX1lyVm8?oc=5", "source_name": "Market source", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Jim Cramer Shares Why Revolution Medicines (RVMD) is Extraordinary", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxONGY5ZEFqdVZla1QtRGd5clpWUEYzRW16MGloQmJvSDhkemJfd1U3R2piNVk4OVN5WGgzSXpzNjNIUThIREJHSHMydmJRdGd2Yjdaazl1bXZLU2lsQXNTNTBPdVlieXdnWFEyOGN1ZVJtMzEwRFVGUjNlc2gydEtBRWhWTlZDd1ZwOHFrLV9BXzEtR0R5bmRBSnpRQ29qZXNpZHpz?oc=5", "source_name": "Market source", "published_at": "2026-04-18T07:00:00+00:00", "published_display": "18 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines Stock Surges After Trial Data: Is Biotech Back?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOeTQyaXg1Mm11QUdxYU9IOWt5X3FBcVROVnBGMXcwSlpUMlRIUWdXdlBLOVpGZkF5SlZ6T1NWd2plcUhfUEJ4RklWZ1Q5TG9hNXdzSFQtOG9sNjBBSk5QZXVhemlXSXdVR2p2VXo1SjMtWENmVC1ZakxmTTlaNFJlbnRPQTJxZnRLbk93ME9BZzdQXzk3M29z?oc=5", "source_name": "EBC Financial Group", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The RAS Revolution: A Deep Dive into Revolution Medicines\u2019 Path to Dominance (2026 Report)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxOaW16emwwZ3NRZGhWdzN2akNfNmFwWi1ONkY5ZDV5ejROejZxbHZJSDU0Z3FoazZzTGdfbDREWTFpSjhxbVJVZmpKZ2JfMjFnSTIwQXc1dXJHRWh5UjU0X21PZG5aOGhtcHR4bmt3d3lra200dWE1cjJFQzAwNUNhT2hEdldTcUV5QjZ2Y1ZabHZxTENoYUhwbDdiUG9XNVNnQnVpdk16QTFRaUY1VVE2bDhyZW9WYjRiemR6Wnh2bnZ5OTJkTmhqZGpWeWtUUzBUM3J1X19CVUQ2ZUtyLTlB?oc=5", "source_name": "FinancialContent", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stocks making the biggest moves premarket: Goldman Sachs, Revolution Medicines, Fastenal & more", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPdTY3RFFleERkQWZuYVplSjN6bkVkTGVUVFJkenk5eElhZWt5QnpxdG5ISmdzMGsyeGVOVThSeERZaDlpcEtPYmRzMndqeVhDeTN2Q3hIS0xuaXQ2WnBTZmdpWnU2Y0FhRDZFeGFiQWdnNllDcnpLWEh2aVhQSXNlT25hMUhmdW42YkI4bVdzR3VUeXd6Zk1DSUFFeEM?oc=5", "source_name": "CNBC", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daraxonrasib boosts survival in Phase 3 pancreatic cancer trial for Revolution Medicines (RVMD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOX19OOTNpdklpV1R4QWVzYkxiMVJOcDJ1NWFrb2IzU2xpdWpxSC1QWU1tQm9mUDExM3B6Qk9HWXVwRU5NUU9ZLU1fa3hnZFBxcDNpRU1Xa3hQcldyWkFRQVJVVldiRzBxZUVwa0pieThITjBHdDVFdDZKVDhDbDNaUWFjcjZIYzlmM3E0Y0pyMFp3YVJxMjMtM0QzNmo2djhYVmVZMW5aOUItSVhneXlOWnV3TQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings Report - Results, Call & Slides", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTFBRRG1qV2VGSWJzeDBHcEpGbjJkRU5rLXAyRmRueDBHS2JVUHJUUXVCRFkxejFWdmZiZ0N6STdLOUluOUp0MWZvcDJhYWp2OXgyN1JPTWZTT1BqRm0xaUVSajhSdzZZeGlDQkJEdA?oc=5", "source_name": "TipRanks", "published_at": "2026-07-22T02:00:49+00:00", "published_display": "22 Jul 2026 02:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines, Inc. (RVMD) Stock Analysis: Why Analysts Are Bullish on This $39.58 Billion Biotech Innovator", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxPeEM0czZYeXNPWGJHOHhjanRYYVhiVGUwcVQ5MlBtRTE1eVIxNEwxY3dRM0pwNXdCYXVnXzBsc2VmLUJFa2lEREs3TTBQcllvVUtXd3owUVc5SHdfdnNCeDJxeFhPTmVMZll5VWpQQTF0VGsxc21WUlI0dXNuSWM3aVY4OVBJSnhtbHlra1I1VEkzZTAxd3BLZDVDb3RxN1JHcU1oMGV1cWdjQklOVG83U1hWV01JOE1wbUFaMVRQRlJ5aG9DVVBUaXRBeWVJblhzT1F4RmJtUlJYYzM2b2tTdHhJd1JyNFNsbWtXQmRQQUJIdw?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-20T09:20:31+00:00", "published_display": "20 Jul 2026 09:20", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Revolution Medicines (RVMD) A Bargain As Daraxonrasib Trial Results Lift Its Outlook?", "summary": "Revolution Medicines (RVMD) is under scrutiny after positive Phase III results for Daraxonrasib and new FDA designations, boosting its stock price significantly. While Simply Wall St's narrative suggests the stock is 39.2% overvalued at $186.16 compared to a fair value of $133.70", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/is-revolution-medicines-rvmd-a-bargain-as-daraxonrasib-trial", "source_name": "Simply Wall Street", "published_at": "2026-07-19T17:10:01", "published_display": "19 Jul 2026 17:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anti-Cancer Upstart\u2019s Stock Surges 125% This Year as Billionaire Druckenmiller Builds Large Position", "summary": "Shares of biotechnology company Revolution Medicines (RVMD) have surged 125% this year, following a significant purchase by billionaire investor Stanley Druckenmiller. The company focuses on developing targeted therapies against previously \"undruggable\" RAS proteins for aggressiv", "url": "https://nai500.com/blog/2026/07/anti-cancer-upstarts-stock-surges-125-this-year-as-billionaire-druckenmiller-builds-large-position/", "source_name": "NAI500", "published_at": "2026-07-18T06:39:54", "published_display": "18 Jul 2026 06:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines Gains as Investors Continue to Digest Clinical and Regulatory Momentum", "summary": "Revolution Medicines (RVMD) saw a 3.1% increase, likely due to continued positive investor sentiment surrounding its pancreatic cancer pipeline. This sentiment follows favorable clinical data updates and a new European regulatory step for daraxonrasib in early July, alongside rai", "url": "https://www.quiverquant.com/news/Revolution+Medicines+Gains+as+Investors+Continue+to+Digest+Clinical+and+Regulatory+Momentum", "source_name": "Quiver Quantitative", "published_at": "2026-07-17T17:35:00", "published_display": "17 Jul 2026 17:35", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors Are Reacting To Revolution Medicines (RVMD) Pancreatic Cancer Data For RAS G12D Inhibitor", "summary": "Revolution Medicines reported promising Phase 1/2 data for its RAS(ON) G12D inhibitor, zoldonrasib, in metastatic pancreatic cancer, showing high response rates and manageable safety. These early results are crucial as there are no approved targeted therapies for RAS G12D cancers", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/how-investors-are-reacting-to-revolution-medicines-rvmd-panc", "source_name": "Simply Wall Street", "published_at": "2026-07-14T10:40:38", "published_display": "14 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines Price Target Raised to $235.00/Share From $205.00 by Guggenheim", "summary": "Guggenheim has increased its price target for Revolution Medicines (NASDAQ:RVMD) to $235.00 per share, up from the previous target of $205.00. This revision suggests a strong positive outlook on the company's future performance. Potential investors should consider this updated va", "url": "https://www.moomoo.com/news/post/72723220/revolution-medicines-price-target-raised-to-235-00-share-from", "source_name": "Moomoo", "published_at": "2026-07-09T20:39:41", "published_display": "09 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Better Growth Buy: Axsome vs Revolution Medicines", "summary": "", "url": "https://finance.yahoo.com/m/7d03d2d0-86ef-3916-a00f-62a03fddbe6b/better-growth-buy%3A-axsome-vs.html", "source_name": "Motley Fool", "published_at": "2026-07-09T08:15:00+00:00", "published_display": "09 Jul 2026 08:15", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines (RVMD) Investor Update Summary", "summary": "Revolution Medicines (RVMD) has announced a significant strategic partnership with Royalty Pharma, securing up to $2 billion in funding without equity dilution, which will support independent global development and commercialization of its RAS(ON) inhibitor portfolio. The company", "url": "https://quartr.com/events/revolution-medicines-inc-rvmd-investor-update_oqBrOIQH", "source_name": "Quartr", "published_at": "2026-07-08T21:11:23", "published_display": "08 Jul 2026 21:11", "sentiment": "positive", "sentiment_pct": 76, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines (RVMD) Wins Faster Reviews, Is The Valuation Already Too Rich?", "summary": "Revolution Medicines (RVMD) is under scrutiny after its drug daraxonrasib received accelerated review for pancreatic cancer and partner drug zoldonrasib showed early trial results. Despite a significant recent share price surge, a common valuation narrative suggests RVMD is 42.5%", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/revolution-medicines-rvmd-wins-faster-reviews-is-the-valuati", "source_name": "Simply Wall Street", "published_at": "2026-07-08T20:28:21", "published_display": "08 Jul 2026 20:28", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "European Medicines Agency Expedites Assessment of Revolution Medicines\u2019 Daraxonrasib Under Phased Review Process", "summary": "The European Medicines Agency (EMA) has initiated a phased review of daraxonrasib, Revolution Medicines\u2019 investigational drug for pancreatic cancer, aiming to accelerate its assessment based on promising Phase 3 trial results. Simultaneously, Revolution Medicines is nearing compl", "url": "https://www.globenewswire.com/news-release/2026/07/07/3323317/0/en/european-medicines-agency-expedites-assessment-of-revolution-medicines-daraxonrasib-under-phased-review-process.html", "source_name": "GlobeNewswire", "published_at": "2026-07-07T21:11:23", "published_display": "07 Jul 2026 21:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines Says Pancreatic Cancer Drug Candidate Daraxonrasib Under EMA Phased Review", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/revolution-medicines-says-pancreatic-cancer-135423289.html", "source_name": "MT Newswires", "published_at": "2026-07-07T13:54:23+00:00", "published_display": "07 Jul 2026 13:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines Says EMA Begins Phased Review of Daraxonrasib for Pancreatic Cancer as FDA NDA Submission Nears Completion", "summary": "Revolution Medicines announced the European Medicines Agency (EMA) has initiated a phased review of its investigational drug, daraxonrasib, for pancreatic cancer, following positive Phase 3 trial results. The drug, designated as an orphan medicinal product by the EMA and a priori", "url": "https://www.quiverquant.com/news/Revolution+Medicines+Says+EMA+Begins+Phased+Review+of+Daraxonrasib+for+Pancreatic+Cancer+as+FDA+NDA+Submission+Nears+Completion", "source_name": "Quiver Quantitative", "published_at": "2026-07-07T13:31:00", "published_display": "07 Jul 2026 13:31", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EMA fast-tracks Revolution Medicines' pancreatic cancer drug review", "summary": "The European Medicines Agency (EMA) has initiated a phased review of Revolution Medicines' investigational drug, daraxonrasib, for pancreatic cancer to expedite its assessment before a full marketing authorization application. This decision is based on positive Phase 3 data from ", "url": "https://www.stocktitan.net/news/RVMD/european-medicines-agency-expedites-assessment-of-revolution-e06zedp7v6mt.html", "source_name": "Stock Titan", "published_at": "2026-07-07T13:11:39", "published_display": "07 Jul 2026 13:11", "sentiment": "positive", "sentiment_pct": 81, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "European Medicines Agency Expedites Assessment of", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAJBVV95cUxOSzkzeWx6T01OT0h0dWVGcHZadkRxY043RGhrdEMwWEpSU3RWWHFWeFNyNXdGS3JRcXZIRnVhSlZKWWE4d0dseDFJTWdzOFpBSkpJTG5JUmE3QUtrY21MMUZWeWtXVFBNUG9UY3hIZks2MnNZcmJ0MTBxODh0VmxybXd2aTlrczJDd1V1WXE5MnFLcm81VmlDdlBlc1RIS3hHLTFWZ0hxak1NU2p5bGNYQ1ZZWFoyWnpMUEl5dXZGUEtEclFGZWQyVVFWRTBCUi1XNkJVbFRVay1xanNORmN4c08wMjFZWjhOSWRsM2VNTE12WFRhSmNkTkFvazExQk1PaU9YU0JCQUpHOVJUZEtYVg?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UBS Adjusts Price Target on Revolution Medicines to $220 From $175, Maintains Buy Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ubs-adjusts-price-target-revolution-141129509.html", "source_name": "MT Newswires", "published_at": "2026-07-06T14:11:29+00:00", "published_display": "06 Jul 2026 14:11", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines stock hits all-time high at 193.12 USD By Investing.com", "summary": "Revolution Medicines Inc. stock has reached an all-time high of $193.12, trading just 1% below its 52-week high, marking a significant 424.05% increase over the past year despite being deemed overvalued by InvestingPro. This surge follows positive Phase 1/2 clinical trial results", "url": "https://za.investing.com/news/stock-market-news/revolution-medicines-stock-hits-alltime-high-at-19312-usd-93CH-4356694", "source_name": "Investing.com South Africa", "published_at": "2026-07-06T14:41:44", "published_display": "06 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Raises Price Target on Revolution Medicines to $215 From $185, Keeps Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/mizuho-raises-price-target-revolution-100609977.html", "source_name": "MT Newswires", "published_at": "2026-07-06T10:06:09+00:00", "published_display": "06 Jul 2026 10:06", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Raises Price Target on Revolution Medicines to $181 From $165, Keeps Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wedbush-raises-price-target-revolution-100418728.html", "source_name": "MT Newswires", "published_at": "2026-07-06T10:04:18+00:00", "published_display": "06 Jul 2026 10:04", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?", "summary": "Revolution Medicines (NASDAQ: RVMD) has seen its stock price surge by nearly 140% in 2026 due to promising late-stage clinical trial results for its cancer treatments, which target previously \"undruggable\" RAS proteins. The company's lead candidate, daraxonrasib, has shown signif", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/motley/3134995/revolution-medicines-is-up-nearly-140-in-2026-is-the-hot-biotech-stock-still-a-buy/", "source_name": "The Globe and Mail", "published_at": "2026-07-06T07:41:44", "published_display": "06 Jul 2026 07:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Strong Early Zoldonrasib Pancreatic Data Change Revolution Medicines' (RVMD) RAS-Focused Narrative?", "summary": "Revolution Medicines reported positive Phase 1/2 data for its oral RAS(ON) G12D inhibitor zoldonrasib in pancreatic cancer, showing high response rates and manageable safety in combination with other treatments. These results support ongoing and planned global Phase 3 trials, str", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/will-strong-early-zoldonrasib-pancreatic-data-change-revolut/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-06T06:39:46", "published_display": "06 Jul 2026 06:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines: A $40 Billion Bet on a Cancer Breakthrough, But At What Price?", "summary": "Revolution Medicines (NASDAQ: RVMD) has seen its market capitalization surge to $40.23 billion due to groundbreaking Phase 3 trial results for its lead cancer drug, daraxonrasib, which showed unprecedented efficacy in metastatic pancreatic cancer. Despite having no revenue and co", "url": "https://www.kavout.com/market-lens/revolution-medicines-a-40-billion-bet-on-a-cancer-breakthrough-but-at-what-price", "source_name": "Kavout | AI", "published_at": "2026-07-06T05:41:50", "published_display": "06 Jul 2026 05:41", "sentiment": "positive", "sentiment_pct": 81, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines, Inc. Warrant Financial Disclosures & SEC Filings", "summary": "This page provides access to Revolution Medicines, Inc. (RVMDW) financial disclosures and SEC filings, including Forms 10-K, 10-Q, 8-K, and other key documents. The filings highlight significant company events such as study results for Daraxonrasib, quarterly earnings, and partic", "url": "https://www.tradingview.com/symbols/NASDAQ-RVMDW/documents/", "source_name": "TradingView", "published_at": "2026-07-05T07:10:29", "published_display": "05 Jul 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026", "summary": "Revolution Medicines, Inc. announced promising Phase 1/2 clinical data for zoldonrasib combination regimens in patients with RAS G12D metastatic pancreatic cancer. The results, presented at the ESMO Gastrointestinal Cancers Congress 2026, show compelling efficacy and manageable s", "url": "https://www.globenewswire.com/news-release/2026/07/02/3321282/0/en/Revolution-Medicines-Presents-Phase-1-2-Clinical-Data-for-Zoldonrasib-Combination-Regimens-in-Patients-with-RAS-G12D-Metastatic-Pancreatic-Cancer-at-ESMO-Gastrointestinal-Cancers-C.html", "source_name": "GlobeNewswire", "published_at": "2026-07-03T06:39:49", "published_display": "03 Jul 2026 06:39", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines Reports 82% Response Rate for Zoldonrasib in Metastatic Pancreatic Cancer", "summary": "Revolution Medicines presented promising Phase 1/2 data for zoldonrasib in metastatic pancreatic ductal adenocarcinoma (PDAC), showing an 82% objective response rate with zoldonrasib plus modified FOLFIRINOX in first-line treatment. The company is advancing two simultaneous Phase", "url": "https://www.clinicaltrialvanguard.com/news/revolution-medicines-reports-82-response-rate-for-zoldonrasib-in-metastatic-pancreatic-cancer/", "source_name": "The Clinical Trial Vanguard", "published_at": "2026-07-03T06:39:00", "published_display": "03 Jul 2026 06:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines (RVMD) Reports Phase 1 2 Pancreatic Cancer Data That Sets Up Phase 3", "summary": "Revolution Medicines (RVMD) has reported promising Phase 1/2 trial data for its RAS(ON) inhibitor combinations, zoldonrasib and daraxonrasib, in metastatic pancreatic cancer. The data showed strong antitumor activity and manageable safety, particularly in patients with RAS G12D m", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/revolution-medicines-rvmd-reports-phase-1-2-pancreatic-cance", "source_name": "Simply Wall Street", "published_at": "2026-07-03T03:10:14", "published_display": "03 Jul 2026 03:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines sees large block trade worth $196.7 million", "summary": "Revolution Medicines Inc. experienced a large block trade of 1.06 million shares, representing 0.5% of its float, valued at $196.7 million. The transaction took place at a 1.3% discount from the opening price. Despite a 0.9% decline on the day of the trade, the stock has gained 1", "url": "https://www.investing.com/news/stock-market-news/revolution-medicines-sees-large-block-trade-worth-1967-million-93CH-4773894", "source_name": "Investing.com", "published_at": "2026-07-02T19:10:14", "published_display": "02 Jul 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines reports trial results for pancreatic cancer drug", "summary": "Revolution Medicines Inc. announced positive results from two Phase 1/2 clinical trials for zoldonrasib in combination regimens for RAS G12D metastatic pancreatic ductal adenocarcinoma. The trials showed promising objective response rates and progression-free survival, supporting", "url": "https://www.investing.com/news/company-news/revolution-medicines-reports-trial-results-for-pancreatic-cancer-drug-93CH-4773016", "source_name": "Investing.com", "published_at": "2026-07-02T13:13:19", "published_display": "02 Jul 2026 13:13", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines reports zoldonrasib pancreatic cancer data", "summary": "Revolution Medicines reported a high treatment response rate of up to 82% for its zoldonrasib combinations in patients with RAS G12D metastatic pancreatic cancer, causing company shares to rise. These Phase 1/2 data, presented at the ESMO GI 2026 Congress, support the initiation ", "url": "https://grafa.com/en/news/united-states/evolution-medicines-zoldonrasib-esmo-2026-data", "source_name": "grafa.com", "published_at": "2026-07-02T13:13:19", "published_display": "02 Jul 2026 13:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines shows 82% response in pancreatic cancer combo trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPRnpqQ0R6bmcxOVJlVDhJaFVzZWlZZFRLc1FBUnJUVlB2RFNfWjR4ekl5OUNrSE1sbGdvSGtQNHJwZF8wM2VZQ1JfWk5SdG5wMzYtNERaOVdTdkJ1cm5YTEtkM1FVZzlENTgwZWdsenJ0WHRnaFdnMFRiWERWWWdkLWFuX2NiMDdpbER6LWwyaUlWYURFVTVBSmNkX0NUa1ZpUVVfUDNfNTFkWmZOUFVWR01R?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Revolution Medicines Inc For: 1 July By Investing.com", "summary": "This article announces the filing of Form 4 for Revolution Medicines Inc. on July 1st. It also provides a market overview with current values for various indices, commodities, and bonds, along with trending news and market movers. The primary content focuses on the Form 4 filing ", "url": "https://ca.investing.com/news/stock-market-news/form-4-revolution-medicines-inc-for-1-july-93CH-4717303", "source_name": "Investing.com Canada", "published_at": "2026-07-01T22:40:48", "published_display": "01 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines (NASDAQ: RVMD) director sells 5,580 shares, exercises options", "summary": "Revolution Medicines director Sushil Patel exercised stock options for 2,955 shares and sold 5,580 shares of RVMD common stock on June 29, 2026. The sales were part of a pre-arranged Rule 10b5-1 trading plan and were executed at weighted-average prices ranging from $182.93 to $19", "url": "https://www.stocktitan.net/sec-filings/RVMD/form-4-revolution-medicines-inc-insider-trading-activity-4823e9b9162c.html", "source_name": "Stock Titan", "published_at": "2026-07-01T22:40:48", "published_display": "01 Jul 2026 22:40", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines director Sushil Patel sells $1.05m in stock By Investing.com", "summary": "Revolution Medicines director Sushil Patel sold $1.05 million worth of company stock through a pre-arranged trading plan, following the exercise of stock options. These sales occurred when the stock was trading near its 52-week high, with InvestingPro analysis suggesting the stoc", "url": "https://ca.investing.com/news/stock-market-news/revolution-medicines-director-sushil-patel-sells-105m-in-stock-93CH-4717300", "source_name": "Investing.com Canada", "published_at": "2026-07-01T22:40:48", "published_display": "01 Jul 2026 22:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Revolution Medicines, Inc. \u2013 NASDAQ:RVMD", "summary": "This article provides a brief financial update for Revolution Medicines, Inc. (NASDAQ: RVMD), focusing on its forward price-to-sales ratio. It indicates current trading information and highlights that the market is closed with no recent trades. The content is primarily a data poi", "url": "https://www.tradingview.com/symbols/NASDAQ-RVMD/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T18:13:20", "published_display": "01 Jul 2026 18:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Revolution Medicines, Inc. \u2013 BMV:RVMD", "summary": "This article provides the \"Price to earnings forward\" metric for Revolution Medicines, Inc. (BMV:RVMD). The content appears to be a financial data point from TradingView, indicating that the market for RVMD was closed with no trades recorded at the time of publication. The articl", "url": "https://www.tradingview.com/symbols/BMV-RVMD/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T05:41:01", "published_display": "01 Jul 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines rises as investors focus on fresh pancreatic cancer pipeline updates | RVMD Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQTjJhc1RHdUhtRXl2Vk5vMm5ZUVI3blRNNTZtbWJsSnpEdjJQelAyRWtCOE1zUXBLUHp5enFyT3ZwUlZaM3BFSkIyRkNKWXBZNF9LU183ZmpOR2xwcWRwb1pHdUtMQlVleUNBNG9fSWcxXzdTRjd5WG5xY1h5RndXUkFWUzFYWm85dHdfWVhJX09TMHRNOVJiTjBnZHdvbzVDXzZUMWtVMzVWSGQ5VThWTXdkMVdEeGpVbHhYX3hGVQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines (NASDAQ: RVMD) insider sells 132,871 shares totaling $19.29M", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOeXJOM2Q2RHZ4ZTNRWGVnWVlOOFh5MEY2THRKZ0tKVVJJc0JuX0tSNU9lblNsNVJVeU85VDkzM2gzR21weUEwUllZYmhDTmoxSDBCdWwyUnEzYUJTTGswSEkzb0JfT0JWc3QxUW1CaWlmSV9BbFdMR3hPN0dHenA2dHVGZnQzLTZLdEYtSXg0dnBmUmNrYzhYUnNHck1Mc09lVkRj?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pancreatic Cancer Drug Milestone Affirms Why Revolution Medicines Inc. (RVMD) is a Hot Stock to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOdUk5S3UzVVgzN1dyVmZ6Nk11N2ZJZklSdTRLZDctSnJtWmJPWVJrTVNMUHA2OFlCVTdHeEFBcXhpRk9PbjRKWTRqVVg3NDFvTjBFZGZQV2RLeDl6Qnd2dE9XYjYxQlRjSWNJSmZYUnJlNVFodHFlQ2czNW4tamdGSm42MFpiVmpoNkhGN1BlLVc4WHFlTThabDZNM2FhRkRZVzNWNVR0WXI?oc=5", "source_name": "Market source", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Revolution Medicines (RVMD) The Best Biotech Stock According to Billionaire Stanley Druckenmiller?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPSTEwbTZXc3lzQXVHdko4YlVDeElMY2JxeWF5R1FPdEVYNi1aVTFPY05JejdBdzVtakYxMVRjeHloR0V1T3FSZEVWSmdwVGxvWXhxSTBJUjQ2Q2xINlBIS3NVZjR2VzVpT3dWUmVlY1FxWjA0Zl9oV2NETFpLeExnWXBzRmlod0doSHpjOUZtbXFiQ2ZGckh2UXR2cHNaaTM4aE9mRXNlR3NCLUU?oc=5", "source_name": "Market source", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNSlhiWmpkRnRZdFZnR1lia0lUcHJRUlJXcXNIWlRNcEFNaTQwWUxDSzNhekZoOEFyMHlhQ0ROaVYtQlRDMjlVaTlKNWJaY3NsTXJfbWduU2tsRkowN2g4c2dTRFRqLXJZM0ExUjV1aTE1RGxkd2NITk93MGZHbGkydjQ5aWZud015NlZXa1c4M1RXTC1oV1JSMVYxNUc?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Daraxonrasib\u2019s Phase 3 Pancreatic Cancer Data And EQRx Deal Altering The Investment Case For Revolution Medicines (RVMD)?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQVEc2R3BwX25pQ20weXhtVVMwcVQ2TlRRYWhBZmx4dm9nZlc4UnRBT2RIT0RCRGdaSlBEZTBtdVk0dFVCNmZSYkhfQ19DVF9CYXIzQVdBY25rM0JUbkdBdm5mRmg5RmxGZ1djdGJ2V0pWQ3FwV3hpWTg0bTJPR0hPbXQzTVlLcFE3bkRZRkg0X3I4WTNZdV8yS1hDOTA4VWZUb2N2cVE4UXRSVUU?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janus Henderson Group reports stake in Revolution Medicines (RVMD) \u2014 9.77M shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOZThwN1NMZ0N6R1p1YjNGb0xFcmxHQkNYRlVIMlJ2NEx3VWtCZmRROXQ3MnRZc0plSVdZQ2xuX18ycFp1OFpJUzBLb2VpTEI0NEhYWUNxMktyTXkxNjFiSTZ4YXhnT2hpa1ZseFc1R0ZacTV3TXhsdnpZZjRVNi02aWhwVWdIOXA0T296QTR1ZHcxSW1sYjNBay0xbi15RE91VE9DZEFWOEFobzZINVduNVZldHdfbDcxdkx0emRRYWZWY3c5clM3VE52NA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug By Reuters", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxPY09oc3ZUaGpNckRvaWdkYWRLSnJEa1Q0MTc3OFRTSlh3aHczR1N6Q2l3MktXSGZxN1VRLTRlcGVEZTh1YWcxbVhKdGpYM2NDT1VsTWljaGRmRzNFb3N2OVZJcDBIa0drOVdTUWR4ZjB3bEVfd2lNSnkwcHJmeWJaQWhuRlY4WTZiYmdWeXdoM0VzRVRQT1hhSUJaS2dIOWlBaG5rVGhvYVE2bmM1b3JpdnhYYVdUWEtFcjhXNEhhc09BTDAtTnhMUTR3aFpmVF9EdFRQUTZMZ2twN3lhNFEyLQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Revolution Medicines (RVMD) After Its Recent Surge In Price?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxQX3UyWVZLTzRKRGdlWTBqcjVmWmpUQUJCOXlKLXZaSjdZRHprZnEwRE1GT3Z1ODZpc1BaUWNNTXlFSXlDWENtZmFwbGVNWGFrSU5JcjZHY2tzcjlqMHBUNXhTc1MtM1NDQWQzVk04cWlYSlpEelRIQm5BZUJpa0trakVpWFduQWw5MkNpWGJ4X250QUNVSHZWV0VXVlVqNS1RWF9UYXlQX195dzJmengyY0NIaXkyN29ZanF1YU9xa1VodHhjb1NZV2Rscjd2MjdzcnJDSUlOLVN6UUlMZndMZ2U1bHBieVZvUGV2QtIB8gFBVV95cUxQSVlDU24yRUN5THM1Wm5BckdkQ1owMFlkdGU3RHZnajNiLXMzWV82WmZCdUFEU09sc3JIb2YybHJDM0tYTGFVX1J0M2JOUUFRZTNYQ3VxMjhwUHZZS0E5bWhEdW5RNVVhMzRSRnpfY2ZyOTVNS3kzWjdXZExCREpTSWFha2pIa1AzWlZIT196WkZ1UE9ZeHd3dXpwVVlYSEFZcFNpc2x3MHB4MVBSQzBlUVF1MDA1UTNqU0ZHQmlSWC1GZTFRUzBjbEdNUjFuU0hzcXRJLXV3T3QxbFYwZlJYbkVEa2ltakNJSGtXWEdPcUlWQQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines (RVMD) Receives FDA\u2019s \u201cSafe to Proceed\u201d Letter for Daraxonrasib", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPM2ZnTzVXbnUzakN2STBHRVVaN0xDdUxmTUtISHVnODhUUklFbnQ2S3NRcjF2YzV5eUphcER0SE4temo0bTVzMFZObHJRaXFTNVItVnVJbzZZcnBWWWFsbXFIUVU5aEpDLXVCRUU0ckFNdFltSlRaaVdYcXpMS0tuNl9UeXg0c0xHOVp3UzlyUlRvNzRUUVgtaVdIblZRem9xQTE1cUdOVVg0WWM?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines, Inc. (RVMD) One of the Best Stocks to Buy in a Rising Market amid $14B Opportunity", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNQl9JUzd3YmpuNFl6clZyRTMwU3MyZmNmeWJOb04za2hyaGp6aWwxZDhCVG1VMXprdkNyUGhMMk9HcS1oazBBbnNVbGZ6NTZ5bEVlNWVseVMwT19SUE5ST2lYZTVKQXdCU3hqTkhQSG44VUpLdlVkZmU2Z0d6QmJfNjBidmNfTzZRWDZySHRPY0prclZWa0dSOHBHX1lyVm8?oc=5", "source_name": "Market source", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jim Cramer Shares Why Revolution Medicines (RVMD) is Extraordinary", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxONGY5ZEFqdVZla1QtRGd5clpWUEYzRW16MGloQmJvSDhkemJfd1U3R2piNVk4OVN5WGgzSXpzNjNIUThIREJHSHMydmJRdGd2Yjdaazl1bXZLU2lsQXNTNTBPdVlieXdnWFEyOGN1ZVJtMzEwRFVGUjNlc2gydEtBRWhWTlZDd1ZwOHFrLV9BXzEtR0R5bmRBSnpRQ29qZXNpZHpz?oc=5", "source_name": "Market source", "published_at": "2026-04-18T07:00:00+00:00", "published_display": "18 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revolution Medicines Stock Surges After Trial Data: Is Biotech Back?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOeTQyaXg1Mm11QUdxYU9IOWt5X3FBcVROVnBGMXcwSlpUMlRIUWdXdlBLOVpGZkF5SlZ6T1NWd2plcUhfUEJ4RklWZ1Q5TG9hNXdzSFQtOG9sNjBBSk5QZXVhemlXSXdVR2p2VXo1SjMtWENmVC1ZakxmTTlaNFJlbnRPQTJxZnRLbk93ME9BZzdQXzk3M29z?oc=5", "source_name": "EBC Financial Group", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The RAS Revolution: A Deep Dive into Revolution Medicines\u2019 Path to Dominance (2026 Report)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxOaW16emwwZ3NRZGhWdzN2akNfNmFwWi1ONkY5ZDV5ejROejZxbHZJSDU0Z3FoazZzTGdfbDREWTFpSjhxbVJVZmpKZ2JfMjFnSTIwQXc1dXJHRWh5UjU0X21PZG5aOGhtcHR4bmt3d3lra200dWE1cjJFQzAwNUNhT2hEdldTcUV5QjZ2Y1ZabHZxTENoYUhwbDdiUG9XNVNnQnVpdk16QTFRaUY1VVE2bDhyZW9WYjRiemR6Wnh2bnZ5OTJkTmhqZGpWeWtUUzBUM3J1X19CVUQ2ZUtyLTlB?oc=5", "source_name": "FinancialContent", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stocks making the biggest moves premarket: Goldman Sachs, Revolution Medicines, Fastenal & more", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPdTY3RFFleERkQWZuYVplSjN6bkVkTGVUVFJkenk5eElhZWt5QnpxdG5ISmdzMGsyeGVOVThSeERZaDlpcEtPYmRzMndqeVhDeTN2Q3hIS0xuaXQ2WnBTZmdpWnU2Y0FhRDZFeGFiQWdnNllDcnpLWEh2aVhQSXNlT25hMUhmdW42YkI4bVdzR3VUeXd6Zk1DSUFFeEM?oc=5", "source_name": "CNBC", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daraxonrasib boosts survival in Phase 3 pancreatic cancer trial for Revolution Medicines (RVMD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOX19OOTNpdklpV1R4QWVzYkxiMVJOcDJ1NWFrb2IzU2xpdWpxSC1QWU1tQm9mUDExM3B6Qk9HWXVwRU5NUU9ZLU1fa3hnZFBxcDNpRU1Xa3hQcldyWkFRQVJVVldiRzBxZUVwa0pieThITjBHdDVFdDZKVDhDbDNaUWFjcjZIYzlmM3E0Y0pyMFp3YVJxMjMtM0QzNmo2djhYVmVZMW5aOUItSVhneXlOWnV3TQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 106, "total_relevant": 62, "sentiment_summary": {"positive": 27, "negative": 4, "neutral": 31, "score": 60, "total": 62, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 15.75, "count": 28}, {"event": "earnings", "label": "Earnings", "weight": 10.86, "count": 22}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}], "positive_events": 27, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 186.16, "latest_week": "2026-07-17", "one_week_move": -0.4, "four_week_move": 14.2, "twelve_week_move": 37.6, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.428852, "market_dynamics_buy_signal": false, "relative_strength": 79.640197, "fair_value_gap": 227.8, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 55.3221, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.4% over one week, +14.2% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 59, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 13}, {"label": "Stock Titan", "count": 6}, {"label": "Simply Wall Street", "count": 5}, {"label": "MT Newswires", "count": 4}, {"label": "TradingView", "count": 4}, {"label": "Quiver Quantitative", "count": 3}, {"label": "GlobeNewswire", "count": 3}, {"label": "Investing.com", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 53}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 28}, {"label": "Earnings", "count": 22}, {"label": "Analyst action", "count": 5}, {"label": "Regulatory and legal", "count": 4}, {"label": "Deals and strategy", "count": 3}]}, "insights": [{"label": "Weighted tone", "value": "60/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "53", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-0.4% over one week, +14.2% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings Report - Results, Call & Slides"}], "updated_at": "2026-07-22T13:37:08.762508+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}